Bolt Stock Based Compensation from 2010 to 2024

BOLT Stock  USD 0.53  0.04  7.02%   
Bolt Biotherapeutics Stock Based Compensation yearly trend continues to be comparatively stable with very little volatility. Stock Based Compensation will likely drop to about 5.4 M in 2024. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals
 
Stock Based Compensation  
First Reported
2019-12-31
Previous Quarter
2.8 M
Current Value
1.1 M
Quarterly Volatility
915.1 K
 
Covid
Check Bolt Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bolt Biotherapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 6.5 M, Interest Income of 6.5 M or Depreciation And Amortization of 2.5 M, as well as many indicators such as Price To Sales Ratio of 5.11, Dividend Yield of 0.0 or PTB Ratio of 0.39. Bolt financial statements analysis is a perfect complement when working with Bolt Biotherapeutics Valuation or Volatility modules.
  
Check out the analysis of Bolt Biotherapeutics Correlation against competitors.
For more information on how to buy Bolt Stock please use our How to Invest in Bolt Biotherapeutics guide.

Latest Bolt Biotherapeutics' Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Bolt Biotherapeutics over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Bolt Biotherapeutics' Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bolt Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
Stock Based Compensation10 Years Trend
Slightly volatile
   Stock Based Compensation   
       Timeline  

Bolt Stock Based Compensation Regression Statistics

Arithmetic Mean2,380,989
Geometric Mean484,070
Coefficient Of Variation156.88
Mean Deviation3,087,450
Median123,000
Standard Deviation3,735,361
Sample Variance14T
Range9.5M
R-Value0.76
Mean Square Error6.4T
R-Squared0.57
Significance0
Slope631,567
Total Sum of Squares195.3T

Bolt Stock Based Compensation History

20245.4 M
20239.2 M
20229.6 M
20218.5 M
20201.4 M
2019508 K

Other Fundumenentals of Bolt Biotherapeutics

Bolt Biotherapeutics Stock Based Compensation component correlations

0.930.90.68-0.810.950.20.930.990.990.870.910.950.45-0.330.59
0.930.930.55-0.70.83-0.161.00.940.950.690.760.820.46-0.260.54
0.90.930.67-0.860.85-0.120.930.90.90.760.810.870.71-0.580.73
0.680.550.67-0.890.730.340.550.70.680.750.80.810.66-0.570.83
-0.81-0.7-0.86-0.89-0.89-0.25-0.7-0.82-0.8-0.9-0.91-0.88-0.840.72-0.92
0.950.830.850.73-0.890.340.830.960.950.960.970.920.56-0.420.71
0.2-0.16-0.120.34-0.250.34-0.160.170.130.50.420.34-0.12-0.050.06
0.931.00.930.55-0.70.83-0.160.940.950.690.760.820.46-0.260.54
0.990.940.90.7-0.820.960.170.941.00.870.910.920.48-0.320.64
0.990.950.90.68-0.80.950.130.951.00.840.890.910.46-0.30.62
0.870.690.760.75-0.90.960.50.690.870.840.990.910.58-0.480.71
0.910.760.810.8-0.910.970.420.760.910.890.990.950.57-0.430.71
0.950.820.870.81-0.880.920.340.820.920.910.910.950.51-0.470.64
0.450.460.710.66-0.840.56-0.120.460.480.460.580.570.51-0.870.94
-0.33-0.26-0.58-0.570.72-0.42-0.05-0.26-0.32-0.3-0.48-0.43-0.47-0.87-0.74
0.590.540.730.83-0.920.710.060.540.640.620.710.710.640.94-0.74
Click cells to compare fundamentals

About Bolt Biotherapeutics Financial Statements

Bolt Biotherapeutics shareholders use historical fundamental indicators, such as Stock Based Compensation, to determine how well the company is positioned to perform in the future. Although Bolt Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Bolt Biotherapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Bolt Biotherapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Stock Based Compensation9.2 M5.4 M
Stock Based Compensation To Revenue 1.17  1.11 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Bolt Stock Analysis

When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.